Insulinoma Clinical Trial
Official title:
Use of Laparoscopy for Localization and Resection of Insulinomas of the Pancreas
This study will determine if laparoscopy can be used successfully to find and remove
insulinomas (insulin-secreting tumors of the pancreas). These tumors are very small and
often difficult to locate with magnetic resonance imaging (MRI), computed tomography (CT) or
ultrasound. Invasive procedures, such as arteriograms (X-ray imaging using a contrast agent
injected into the bloodstream through a catheter) and venous sampling are more successful
but involve more patient discomfort and greater risk. This study will test whether
laparoscopy can be used to replace some or all of these tests, as well as more extensive
surgery.
Patients 11 years of age and older with low blood sugar (hypoglycemia) probably caused by an
insulinoma may be eligible for this study. Candidates will have their hypoglycemia confirmed
(with tests done under NIH protocol 91-DK-0066: Diagnosis and Treatment of Hypoglycemia) and
will have CT imaging of the abdomen and MRI and ultrasound tests of the liver and pancreas.
Patients whose tumors are not found by these studies will undergo arteriography of the
pancreas and hepatic (liver) venous sampling.
Patients will then have laparoscopy. This surgical procedure uses a laparoscope-a tube-like
device with special cameras and an ultrasound probe attached through which the surgeon can
see and operate inside the abdomen. Laparoscopy is commonly done to remove the gallbladder
and is also used to remove portions of the pancreas. For the current procedure, the surgeon
makes small incisions in the abdomen, inserts tubes, fills the abdomen with gas, and
proceeds to explore and operate on the pancreas. The surgeon will try to locate the tumor
with the laparoscope. If the tumor is found, the location will be verified by the imaging
study results. If it cannot be located by laparoscopy, the results of the imaging studies
will be disclosed to enable removal. If the tumor cannot be successfully removed using the
laparoscope, standard surgery will then be performed. If the tumor cannot be found though
laparoscopy, imaging studies, or traditional surgery, the operation will be concluded
without removing any of the pancreas. Medical treatment will be initiated and re-evaluation
will be recommended after 6 months.
Patients with the clinical diagnosis of hypoglycemia secondary to a putative insulin secreting pancreatic neuroendocrine tumor require accurate localization of the tumor and definitive surgical resection. Non-invasive pre-operative imaging studies such as CT, MRI and ultrasound often fail to accurately localize the lesion prior to surgery. Invasive imaging such as arteriogram and selective arterial stimulation are a major improvement, but may not be needed in all patients. This trial will evaluate the ability of laparoscopic exploration with intraoperative ultrasound to localize the insulinoma and allow for its resection with a single procedure. ;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02021604 -
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
|
Phase 1 | |
Withdrawn |
NCT02108782 -
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Active, not recruiting |
NCT05034783 -
[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients
|
Early Phase 1 | |
Terminated |
NCT02273752 -
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
|
Phase 2 | |
Completed |
NCT00937079 -
Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients
|
Phase 1 | |
Recruiting |
NCT04185350 -
Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma
|
Early Phase 1 | |
Recruiting |
NCT00001276 -
Diagnosing and Treating Low Blood Sugar Levels
|
||
Active, not recruiting |
NCT02121366 -
EUS-guided Ethanol Ablation of an Insulinoma
|
N/A | |
Terminated |
NCT00084461 -
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00131911 -
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
|
Phase 2 | |
Recruiting |
NCT03583528 -
DOTATOC PET/CT for Imaging NET Patients
|
||
Withdrawn |
NCT04915144 -
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
|
Phase 2 | |
Recruiting |
NCT05523778 -
A Multi-center Study to Evaluate the Efficacy and Safety of Pancreatic Duct Stents Placement Before the Enucleation of Insulinoma Located in the Head and Neck of the Pancreas Near the Main Pancreatic Duct
|
N/A | |
Recruiting |
NCT02560376 -
68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis
|
Phase 0 | |
Completed |
NCT01525082 -
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00655655 -
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00075439 -
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
|
Phase 2 | |
Terminated |
NCT04452396 -
CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia
|
N/A | |
Active, not recruiting |
NCT01824875 -
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00004074 -
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
|
Phase 1 |